How Is Canavan Gene Therapy Trial Eligibility Determined?

Finding out if your child is eligible for an emerging gene therapy clinical trial—such as those for MYR-101 (NCT04833907) or BBP-812—can feel urgent and overwhelming. Because these therapies are early-phase and experimental, clinical trials use strict study protocols, which include specific inclusion and exclusion criteria. These criteria are not just suggestions; they are designed to ensure the treatment is as safe as possible and to help researchers accurately measure its effects ^[1]. Eligibility is determined exclusively by the trial’s study site, and passing an initial screen does not guarantee enrollment or medical benefit.

Illustrative Eligibility Factors

Every clinical trial has its own highly specific requirements. The factors below are illustrative examples of what gene therapy trials for Canavan disease typically evaluate.

Confirmed Genetic Diagnosis

Canavan disease is caused by mutations in the ASPA gene. Clinical trials generally require definitive molecular proof of this genetic cause ^[2].

• Biallelic pathogenic variants (genetic changes that are known to cause disease, with one located on each copy of the gene) are typically required ^[3].
• If standard genetic testing only finds one variant, a genetics team may need to perform additional testing—such as deletion/duplication analysis or long-read sequencing (an advanced genetic test that can find hidden structural changes in DNA) ^[4].
• Biochemical diagnosis evidence, like elevated N-acetylaspartate (NAA) levels, can support the diagnosis but usually cannot replace the requirement for molecular genetic proof ^[5].

Age and Disease Phenotype

Gene therapies often target children at specific stages of development.

• Age Limits: Trials may have strict age minimums or maximums, meaning a child must be treated within a precise age window.
• Disease Type: A trial might focus on “typical” Canavan disease—often marked by profound developmental delays early in life—or it might evaluate children with a milder progression separately ^{[5] [6]}. Parents cannot self-classify their child’s disease stage; the trial team will evaluate the child’s functional milestones.

Baseline Imaging and Biochemical Tests

To measure whether the therapy works, a trial needs to establish a child’s baseline (their starting medical condition). Trials may require specific types of magnetic resonance imaging (MRI), magnetic resonance spectroscopy (a specialized imaging technique that measures chemicals like NAA in the brain), or urine tests to measure NAA ^{[7] [5]}. The trial site will specify exactly which tests are required and when they should be performed.

AAV Antibodies

Gene therapies for Canavan disease often use a modified, replication-incompetent (unable to multiply) Adeno-Associated Virus (AAV) as a vector (a delivery vehicle) to carry the working ASPA gene into the brain ^[1].

• If a child has been exposed to a similar natural virus, their immune system may have created neutralizing antibodies (protective proteins) against it ^[8].
• High levels of these antibodies might neutralize the vector, preventing the therapy from reaching its target and working. Therefore, antibody levels are often an exclusion criterion ^[8].
• Because different trials use different AAV vectors (e.g., AAV9 vs. AAV-Olig001), the screening tests and antibody cutoffs are specific to each trial ^{[9] [10]}.

General Medical Exclusions

A trial may exclude patients if they have severe liver or kidney disease, active infections, immune disorders, or have previously received another gene therapy ^[11].
Note: Never stop or change your child’s medications, supplements, or supportive care to try to qualify for a trial without explicit instructions from your treating clinician.

What Participation Involves (Risks and Unknowns)

Participating in an experimental gene therapy trial is a massive commitment and carries unknown risks. Depending on the trial, participation may involve:

• Invasive Procedures: The therapy may be delivered directly into the brain or spinal fluid, requiring neurosurgery, lumbar punctures, and anesthesia ^[1].
• Immunosuppression: Children may need to take strong steroids or immune-suppressing medications for months to prevent dangerous immune reactions ^[2].
• Long-Term Burden: Families must often commit to years of follow-up visits, hospitalizations, and monitoring.
• Uncertain Benefit: It is unknown if the therapy will work, and it may not reverse neurological injury that has already occurred.

Actionable Steps for Parents

To explore eligibility while avoiding unnecessary expenses or incorrect tests, follow these steps in order:

1. Verify Trial Status: Search for “Canavan disease” on ClinicalTrials.gov. Look for specific trials like MYR-101 (NCT04833907">NCT04833907). Check if the status is “Recruiting.” (Note: As of current research, comprehensive public criteria for BBP-812 are unresolved).
2. Contact the Study Site First: Use the “Contacts and Locations” section on the registry to reach the trial coordinator. Ask them exactly which tests and records they require. Do not arrange outside MRI or AAV antibody testing until the trial specifies their required methods and laboratories.
3. Consult Your Team: Discuss the trial’s requirements and risks with your pediatric neurologist and a clinical genetic counselor.
4. Gather Specified Records: Collect the original genetic testing reports, developmental assessments, and a complete medication list to send to the study coordinator for pre-screening.